Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) FCF Margin (2023)

Historic FCF Margin for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to 81.29%.

  • Contineum Therapeutics' FCF Margin changed N/A to 81.29% in Q2 2023 from the same period last year, while for Mar 2024 it was 32.22%, marking a year-over-year change of. This contributed to the annual value of 37.87% for FY2023, which is N/A changed from last year.
  • Per Contineum Therapeutics' latest filing, its FCF Margin stood at 81.29% for Q2 2023.
  • Contineum Therapeutics' FCF Margin's 5-year high stood at 5756.52% during Q1 2023, with a 5-year trough of 81.29% in Q2 2023.